Long-Term clinical outcomes according to initial management and thrombolysis in myocardial infarction risk score in patients with acute non-ST-segment elevation myocardial infarction. by �옣�뼇�닔 & 理쒕룞�썕
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 201058
Original Article DOI 10.3349/ymj.2010.51.1.58pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 51(1): 58-68, 2010
Long-Term Clinical Outcomes according to 
Initial Management and Thrombolysis 
In Myocardial Infarction Risk Score in Patients with
Acute Non-ST-Segment Elevation Myocardial Infarction
Hae Chang Jeong,1 Youngkeun Ahn,1 Myung Ho Jeong,1 Shung Chull Chae,2 Seung Ho Hur,3
Taek Jong Hong,4 Young Jo Kim,5 In Whan Seong,6 Jei Keon Chae,7 Jay Young Rhew,8
In Ho Chae,9 Myeong Chan Cho,9 Jang Ho Bae,10 Seung Woon Rha,11 Chong Jin Kim,12
Donghoon Choi,13 Yang Soo Jang,13 Junghan Yoon,14 Wook Sung Chung,15 Jeong Gwan Cho,1
Ki Bae Seung,16 Seung Jung Park,17 and Other Korea Acute Myocardial Infarction Registry
Investigators 
Korea Acute Myocardial Infarction Registry (KAMIR) Study Group of Korean Circulation Society
1Department of Internal Medicine, Chonnam National University Hospital, Gwangju; 2Department of Internal Medicine, 
Kyungpook National University, Daegu; 3Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu;
4Department of Internal Medicine, Pusan National University Hospital, Busan; 5Department of Internal Medicine, Yeungnam University
Hospital, Daegu; 6Department of Internal Medicine, Chungnam National University Hospital, Daejeon; 7Department of Internal Medicine,
Chonbuk National University Hospital, Jeonju; 8Department of Internal Medicine, Jeonju Presbyterian Medical Center, Jeonju; 
9Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam; 10Department of Internal Medicine, National
University, Cheongju; 11Department of Internal Medicine, Konyang University, Daejeon; 12Department of Internal Medicine, 
Korea University Guro Hospital, Seoul; 13Department of Internal Medicine, Kyung Hee University Hospital, Seoul; 
14Department of Internal Medicine, Yonsei University Wonju Hospital, Wonju; 15Department of Internal Medicine, 
Wonju University Hospital, Wonju; 16Department of Internal Medicine, Catholic University Hospital, Seoul; 
17Department of Internal Medicine, Asan Medical Center, Seoul, Korea.
Purpose: There is still debate about the timing of revascularization in patients
with acute non-ST-segment elevation myocardial infarction (NSTEMI). We
analyzed the long-term clinical outcomes of the timing of revascularization in
patients with acute NSTEMI obtained from the Korea Acute Myocardial
Infarction Registry (KAMIR). Materials and Methods: 2,845 patients with
acute NSTEMI (65.6 ± 12.5 years, 1,836 males) who were enrolled in KAMIR
were included in the present study. The therapeutic strategy of NSTEMI was
categorized into early invasive (within 48 hours, 65.8 ± 12.6 years, 856 males)
and late invasive treatment (65.3 ± 12.1 years, 979 males). The initial- and
long-term clinical outcomes were compared between two groups according to
the level of Thrombolysis In Myocardial Infarction (TIMI) risk score. Results:
There were significant differences in-hospital mortality and the incidence of
major adverse cardiac events during one-year clinical follow-up between two
groups (2.1% vs. 4.8%, p < 0.001, 10.0% vs. 13.5%, p = 0.004, respectively).
According to the TIMI risk score, there was no significant difference of long-
term clinical outcomes in patients with low to moderate TIMI risk score, but
significant difference in patients with high TIMI risk score (≥ 5 points). 
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The recent guidelines of the American College of Cardio-
logy-American Heart Association (ACC/AHA) and the
European Society of Cardiology (ESC) recommended an
early invasive approach for the high-risk patients who
suffer from acute coronary syndromes without ST-
segment elevation.1-4 Despite these recommendations, it is
not clear whether an early invasive strategy reduces mor-
tality in non-ST-elevation myocardial infarction (NSTEMI)
patients. Recent Invasive versus Conservative Treatment
in Unstable Coronary Syndromes (ICTUS) trial did not
show superiority of an early invasive strategy for NSTEMI
patients at the 1-year and 4-year clinical follow-up.5,6
However, such recent advances in medical therapy as the
early use of clopidogrel and intensive lipid-lowering
therapy have been shown to improve the prognosis for
patients suffering from acute coronary syndrome.7,8
Therefore, we undertook the present study to analyze the
clinical efficacy of the timing of revascularization and to
test the hypothesis that an early invasive strategy is superior
to a late invasive strategy for treating the NSTEMI patients
who are registered in the Korea Acute Myocardial Infarc-
tion Registry (KAMIR). We compared two large patient
cohorts obtained from the 50 multi-center KAMIR; one
consisting of consecutive acute myocardial infarction pati-
ents treated with early invasive strategy and the other
patients treated with late invasive strategy. 
Patients population and study design
The KAMIR is a prospective, multi-center, observational
registry designed to examine current epidemiology, in-
hospital management, and outcome of patients with acute
MI in Korea for the commemoration of the 50th anni-
versary of the Korean Circulation Society.9,10 Fifty high
volume university, community centers with percutaneous
coronary intervention (PCI) facilities and on-site cardiac
surgery comprise the KAMIR. 2,845 patients (65.6 ± 12.5
years, 1,836 males) who were followed-up for one-year
were included in the present study. Eligible patients for
this study were required to have all three of the following:
1) symptoms of ischemia increasing or occurring at rest, 2)
an elevated cardiac troponin I level (≥ 2.0 ng/mL) or CK-
MB (19 U/L, exceeding twice the upper limit of normal),
and 3) ischemic changes assessed by electrocardiography,
defined as ST-segment elevation, depression, or T-wave
inversion of ≥ 0.2 mV in two contiguous leads.
We analyzed baseline demographic and clinical charac-
teristics, relevant laboratory results, and pharmacotherapy.
And we calculated Thrombolysis In Myocardial Infarc-
tion (TIMI) risk score11 of each patients at admission to
Emergency Department. Echocardiography was per-
formed in all patients before discharge. Major adverse
cardiac events (MACE) at the six-month and one-year
clinical follow-up were evaluated and were defined as the
composite of 1) all cause death, 2) non-fatal MI, and 3) re-
PCI or coronary artery bypass graft. Re-infarction was
defined as the recurrence of symptoms or electrocar-
diographic changes in association with a rise in cardiac
enzymes above the normal upper limit. All data were
recorded on a standardized, electronic, web-based registry
at http://www.kamir.or.kr.
Pre and post-intervention management
Prior to the index intervention, all patients received 300
mg of aspirin and 450 to 600 mg of clopidogrel. After the
procedure, patients were maintained on aspirin 100-200
mg indefinitely. Clopidogrel 75 mg per day was prescribed
for a minimum of 4 weeks in patients treated with bare
metal stent (BMS) and for a minimum of 6 months in pati-
ents treated with drug-eluting stent (DES). The duration of
clopidogrel therapy and triple anti-platelet therapy, includ-
ing cilostazol, after the procedure was left to the discretion
of the operator and referring physicians. 
Treatment strategy
The patients who were assigned to the early invasive
strategy group (Group I: 65.8 ± 12.6 years, 856 males)
were scheduled to undergo angiography within 48 hours
after hospitalization and then PCI was performed when
appropriate; the decision to perform PCI was based on the
coronary anatomy. The patients who were assigned to the
late invasive strategy group (Group II: 65.3 ± 12.1 years,
979 males) were treated medically first. These patients
were scheduled to undergo angiography and subsequent
revascularization only if they had refractory angina despite
Non-ST Elevation Myocardial Infarction in KAMIR
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INTRODUCTION
MATERIALS AND METHODS
Conclusion: The old age, high Killip class, low ejection fraction, high TIMI risk score, and late invasive treatment
strategy are the independent predictors for the long-term clinical outcomes in patients with NSTEMI.
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Table 1. Baseline Clinical Characteristics and Hemodynamics 
Characteristics
Group I Group II
p
(n = 1,234) (n = 1,611)
Mean age (yrs) 65.8 ± 12.6 65.3 ± 12.1 0.361
Male (%) 856 (69.4) 979 (60.8) < 0.001
Body mass index (kg/m2) 24.3 ± 3.6 23.5 ± 3.2 0.866
Past history (%)
Hypertension 647 (52.5) 573 (54.2) 0.271
Diabetes mellitus 401 (32.4) 551 (34.2) 0.051
Smoking 704 (57.1) 750 (46.6) < 0.001
Hyperlipidemia 148 (12.0) 157 (9.7) 0.057
Family history of heart disease 98 (7.9) 70 (4.4) < 0.001
Prior angina 106 (8.6) 126 (7.8) 0.368
Prior myocardial infarction 65 (5.3) 91 (5.6) 0.627
Prior percutaneous coronary intervention 98 (7.9) 119 (7.4) 0.507
Prior coronary artery bypass graft 11 (0.9) 30 (1.9) 0.027
Symptom to door time (min) 1,444.0 ± 401.3 1,488.4 ± 349.2 0.761
Symptoms and hemodynamic on admission
Dyspnea (%) 315 (25.5) 583 (36.2) < 0.001
Systolic blood pressure (mmHg) 132.5 ± 26.3 132.1 ± 29.8 0.686
Heart rate (beats/min) 78.2 ± 25.6 79.8 ± 22.6 0.566
Killip class (%)
I 973 (78.8) 1,065 (66.1) < 0.001
II 139 (11.3) 255 (15.8) < 0.001
III 92 (7.5) 224 (13.9) < 0.001
IV 30 (2.4) 67 (4.2) < 0.001
TIMI risk score 3.4 ± 1.3 3.4 ± 1.3 0.646
Low risk (TIMI risk score 0 - 2) 310 (25.1) 432 (26.8) 0.308
Moderate risk (TIMI risk score 3 - 4) 687 (55.7) 869 (53.9) 0.358
High risk (TIMI risk score 5 - 7) 237 (19.2) 310 (19.2) 0.980
Electrocardiogram findings
ST segment depression ≥ 0.1mV 486 (39.4) 645 (40.0) 0.480
Echocardiogram findings
Left ventricular ejection fraction (%) 54.6 ± 12.1 54.6 ± 24.5 0.803
Total wall motion score 17.4 ± 10.2 18.2 ± 10.4 0.442
Laboratory findings
Creatine clearance (mL/min) 880.8 ± 1,254.3 658.6 ± 1,238.9 < 0.001
Creatine kinase-MB (U/L) 101.2 ± 307.8 53.9 ± 84.6 < 0.001
Troponin I (ng/mL) 26.6 ± 57.2 18.1 ± 42.7 < 0.001
Troponin T (ng/mL) 8.4 ± 84.4 7.2 ± 66.0 0.111
Total cholesterol (mg/dL) 184.6 ± 44.6 180.4 ± 47.3 0.018
Triglyceride (mg/dL) 136.1 ± 106.6 126.5 ± 85.1 0.013
High density lipoprotein-cholesterol (mg/dL) 46.1 ± 26.8 45.0 ± 16.4 0.188
Low density lipoprotein-cholesterol (mg/dL) 119.6 ± 43.3 115.0 ± 43.8 0.251
High sensitivity C-reactive protein (mg/dL) 2.2 ± 8.6 2.1 ± 10.3 0.873
N-terminal pro-brain natriuretic peptide (pg/mL) 2,381.9 ± 5,920.8 5,149.6 ± 9,320.7 < 0.001
TIMI, Thrombolysis In Myocardial Infarction.
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optimal medical treatment or they had hemodynamic or
rhythmic instability.
Statistical analysis
We compared the in-hospital mortality, the admission dur-
ation of coronary care unit, and the incidence of MACE
during one-year clinical follow-up between two groups.
The subgroup analysis was done according to each TIMI
risk score and several baseline clinical features including
age, gender, the presence or absence of diabetes mellitus,
the presence or absence of ST-segment deviation, or the
level of glomerular filtration rate. And the predictive factors
for MACE at one-year clinical follow-up were calculated
by multiple logistic regression analysis. 
The statistical Package for Social Sciences (SPSS) for
Windows, version 15.0 (Chicago, IL, USA) was used for
all analyses. Continuous variables with normal distri-
butions were expressed as mean ± SD and they were
Non-ST Elevation Myocardial Infarction in KAMIR
Yonsei Med J   http://www.eymj.org    Volume 51   Number 1   January 2010 61
Table 2. Medical Therapy at Discharge 
Medical therapy (%)
Group I Group II
p
(n = 1,234) (n = 1,611)
Aspirin 1,174 (95.1) 1,521 (94.4) 0.271
Clopidogrel 1,136 (92.1) 1,481 (92.0) 0.284
Cilostazol 375 (30.4) 371 (23.0) < 0.001
Statin 912 (73.9) 1,176 (73.0) 0.068
Beta blocker 861 (69.8) 1,125 (69.8) 0.707
Angiotensin converting enzyme inhibitor 737 (59.7) 937 (58.2) 0.402
Angiotensin receptor blocker 251 (20.3) 278 (17.3) 0.041
Table 3. Baseline Coronary Angiographic Variables 
Variable
Group I Group II
p
(n = 1,234) (n = 1,611)
Coronary angiogram (%) 1,234 (100.0) 1,506 (93.5) 0.076
Coronary artery disease (%)
1 vessel 431 (34.9) 539 (35.8) 0.147
2 vessels 406 (32.9) 503 (33.4) 0.076
3 vessels 344 (27.9) 398 (26.4) 0.885
Left main, isolated 6 (0.5) 6 (0.4) 0.966
Left main, complex 47 (3.8) 60 (3.9) 0.373
Infarct-related artery (%)
Left main 48 (3.9) 55 (3.4) 0.070
Left anterior descending artery 480 (38.9) 585 (38.8) 0.927
Right coronary artery 327 (26.5) 467 (31.0) 0.021
Left circumflex artery 379 (30.7) 429 (28.4) 0.044
Lesion type (%)*
A 60 (4.9) 104 (6.9) 0.044
B1 225 (18.2) 248 (16.5) 0.284
B2 337 (27.3) 389 (25.8) 0.398
C 612 (49.6) 765 (50.8) 0.541
TIMI flow grade (%)
0 399 (32.3) 317 (21.0) < 0.001
1 169 (13.7) 197 (13.1) 0.677
2 249 (20.2) 245 (16.3) 0.017
3 417 (33.8) 747 (49.6) < 0.001
TIMI, Thrombolysis In Myocardial Infarction.
*Lesion type according to American College of Cardiology/American Heart Association classification.
compared with the use of an unpaired Student’s t-test.
Categorical variables were compared with the use of the
chi-square test, where appropriate. The relative risks were
calculated by dividing the Kaplan-Meier estimated rate of
an event in the early invasive strategy group by that of the
late invasive strategy group. The 95 percent confidence
interval for the relative risk was calculated with the use of
the standard errors from the Kaplan-Meier curve. A p less
than 0.05 was deemed as significant. We performed a pro-
pensity score analysis to adjust for imbalances in baseline
characteristics between early invasive group and late inva-
sive group. We used logistic regression model to derive a
propensity score for early invasive strategy that included
63 variables.
Baseline clinical characteristics of the study population
Among the 2,845 patients with NSTEMI who were follow-
ed-up during one-year there were 1,234 early invasive
treatment strategy patients and 1,611 late invasive strategy
patients. The baseline clinical characteristics of the study
population are described in Table 1. 
Medical therapy during hospitalization
For medical therapy at discharge, significant differences in
the proportions of patients receiving particular drugs were
observed. Cilostazol and angiotensin receptor blocker were
more frequently used in group I, as shown in Table 2. And
other medications at discharge are also shown in Table 2.
Coronary angiographic findings
In the early invasive strategy group, coronary angiography
was done in 100% of patients during hospitalization,
compared with 93.5% in the late invasive strategy group.
The baseline coronary angiographic characteristics are
shown in Table 3. Approximately 65% of the patients had
multi-vessel diseases. The most common infarct-related
artery was the left anterior descending artery in both groups.
A lesion type B2 or C, according to the ACC/AHA classi-
fication, was present in 76.9% of group I patients and
76.6% of group II patients. A TIMI flow grade 2 or 3 was
observed in 54.0% of group I patients and 65.9% of group
II patients.
Procedural characteristics
As shown in Table 4, PCI was tried in 100% of patients in
group I, during hospitalization. The mean door to balloon
Hae Chang Jeong, et al.
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RESULTS
Table 4. Procedural Characteristics
Variable
Group I Group II
p
(n = 1,234) (n = 1,611)
Percutaneous coronary intervention 1,234 (100.0) 1,145 (71.1) < 0.001
Door to balloon time (min) 1,144.5 ± 1,202.6 6,360.9 ± 5,010.5 < 0.001
Procedural success (%) 1,177 (95.4) 1,089 (95.1) 0.254
Stent type (%)
Bare metal stent 76 (6.8) 76 (7.4) 0.661
Drug eluting stent 1,044 (93.2) 954 (92.6) 0.305
Stent size (mm) 3.1 ± 0.4 3.1 ± 0.4 0.227
Stent length (mm) 25.2 ± 6.4 25.6 ± 7.4 0.219
Number of stents implanted per patients 1.66 ± 0.972 1.69 ± 0.917 0.573
Final TIMI flow grade (%)
0 23 (1.9) 34 (3.0) 0.109
1 7 (0.6) 18 (1.6) 0.017
2 40 (3.2) 30 (2.6) 0.378
3 1,164 (94.3) 1,063 (92.8) 0.157
Coronary artery bypass graft (%) 14 (1.1) 131 (8.1) < 0.001
Revascularization (%)
Complete revascularization 176 (14.2) 245 (15.2) 0.545
Revascularization of single IRA 442 (35.8) 433 (26.9) < 0.001
Revascularization of only IRA in multi-vessel 394 (32.0) 340 (21.1) < 0.001
Multi-vessel revascularization 179 (14.5) 251 (15.6) 0.471
No revascularization of IRA 43 (3.5) 342 (21.2) < 0.001
TIMI, Thrombolysis In Myocardial Infarction; IRA, infarct related artery. 
time was 1,144 ± 1,202 minutes. PCI was done success-
fully in 95.4% patients. Coronary bypass graft surgery was
done in 1.1% during hospitalization. Total revasculariza-tion
rate was 96.5%. In group II, PCI was tried in 71.7% of the
patients during hospitalization. The mean door to balloon
time was 6,360 ± 5,010 minutes (vs. group I, p < 0.001).
The success rate was 95.1%. Coronary bypass graft surgery
was done in 8.1% (vs. group I, p < 0.001) during hospitali-
zation. Total revascularization rate was 78.8% (vs. group I, p
< 0.001). The average diameter, length, and number of stent
were not significantly different between two groups.
In hospital outcomes according to TIMI risk score
The estimated in-hospital mortality was 2.1% in group I
and 4.8% in group II (relative risk: 2.36, 95% confidence
interval: 1.51 to 3.71; p < 0.001) (Table 5). The patients in
both groups were classified into 3 sub-groups according to
the TIMI risk score: 742 patients (310 patients of group I
and 432 patients of group II) had a TIMI risk score of 0-2
points (the low risk group), 1,556 patients (687 patients of
group I and 869 patients of group II) had a TIMI risk score
of 3-4 points (the moderate risk group) and 547 patients
(237 patients of group I and 310 patients of group II) had a
TIMI risk score of 5-7 points (the high risk group). For the
low and moderate and high risk patients, no significant
differences of the in-hospital mortality (p = 0.872, p = 0.052,
respectively) were observed between two groups. However,
for the high risk patients, there was a significantly lower
in-hospital mortality in group I (3.3% vs. 8.9%, respectively,
p < 0.001). And the duration of admission to the coronary
care unit was significantly longer in group II (3.1 vs. 5.2
days, p < 0.001).
MACE at six-months and one-year according to TIMI
risk score
The incidence of MACE was 10.0% in group I and 13.5%
in group II (p = 0.004) at one-year clinical follow-up. The
composite of MACE is described in Table 5. The rate of
cardiac death was higher in group II during six-months and
one-year clinical follow-up (p < 0.001, p < 0.001 respecti-
vely). However, the rate of re-PCI (especially, the rate of
revascularization of non-target vessel) was higher in group
I (p = 0.002 at six-months, p = 0.001 at one-year).
In the subgroup analysis according to each TIMI risk
score, there was no significant difference in the incidence
of MACE during one-year clinical follow-up in patients
with TIMI risk score between 1 and 4. However, incidence
of MACE was significantly lower in patients of group I
Non-ST Elevation Myocardial Infarction in KAMIR
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Table 5. Clinical Outcomes during One-Year Follow-Up
Variable
Group I Group II
p
(n = 1,234) (n = 1,611)
Outcomes in-hospital period
In-hospital death 26 (2.1) 77 (4.8) < 0.001
Coronary care unit admission duration (days) 3.1 ± 3.1 5.2 ± 5.7 < 0.001
The composite of MACE at 6-months 106 (8.6) 200 (12.4) < 0.001
Cardiac death 37 (3.0) 123 (7.6) < 0.001
Non-cardiac death 5 (0.4) 17 (1.1) 0.050
Myocardial infarction 12 (1.0) 24 (1.5) 0.221
Re-percutneous coronary intervention 46 (3.7) 30 (1.9) 0.002
Target vessel revascularization 7 (0.6) 3 (0.2) 0.089
Non-target vessel revascularization 25 (2.0) 15 (0.9) 0.014
Target lesion revascularization 16 (1.3) 12 (0.7) 0.140
Coronary artery bypass graft 6 (0.5) 6 (0.4) 0.643
The composite of MACE at one-year 123 (10.0) 218 (13.5) 0.004
Cardiac death 38 (3.1) 125 (7.8) < 0.001
Non-cardiac death 7 (0.6) 21 (1.3) 0.049
Myocardial infarction 16 (1.3) 29 (1.8) 0.286
Re-percutneous coronary intervention 55 (4.5) 37 (2.3) 0.001
Target vessel revascularization 10 (0.8) 5 (0.3) 0.068
Non-target vessel revascularization 29 (2.4) 18 (1.1) 0.011
Target lesion revascularization 18 (1.5) 15 (0.9) 0.193
Coronary artery bypass graft 7 (0.6) 6 (0.4) 0.445
MACE, major adverse cardiac event.
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Fig. 1. Primary end point (one-year major adverse cardiac events) according to the Thrombolysis In Myocardial Infarction (TIMI) risk score.
Variable No (%) Relative risk (95% confidential interval) Rate of primary end point (%)     
Gropu I Group II p
Overall 2,845 (100) 123 (10.0) 217 (13.5) 0.004
Age < 65 1,187 (41.7) 46 (7.8) 39 (6.5) 0.381
Age ≥ 65 1,658 (58.3) 77 (11.9) 178 (17.6) 0.002
Male sex 1,835 (64.5) 77 (9.0) 117 (12.0)    0.040
Female sex 1,010 (35.5) 46 (12.2)    100 (15.9)    0.103
Diabetes 952 (33.5) 39 (9.7) 109 (19.8)     < 0.001
No diabetes 1,893 (66.5) 84 (9.7) 108 (10.3)  0.668
GFR ≥ 60 mL/min 1,544 (54.3) 62 (7.8)     53 (7.0)      0.540
GFR < 60 mL/min 1,301 (45.7) 61 (13.7) 164 (19.1)   0.015
ST depression 1,131 (39.8) 56 (11.5)   107 (16.6)   0.037
No ST depression 1,714 (60.2) 67 (8.7)     110 (11.7)  0.091 
Fig. 2. Estimated rates and relative risk of the composite primary end points of death from cardiac or non cardiac causes, recurrent myocardial
infarction, target vessel or non-target vessel or target lesion revascularization at one year according to subgroups.
with TIMI risk score between 5 and 7 (Fig. 1).
Subgroup analysis according to age, gender, diabetes,
renal function, and ST segment depression
For patients with old age (over 65 years), male, diabetes
mellitus, lower GFR (below 60 mL/min), and the presence
of ST segment depression, the incidence of MACE was
lower in group I (relative risk: 1.577, 1.373, 2.014, 1.486,
1.402, p = 0.002, 0.040, < 0.001, 0.015, 0.037, respectively)
(Fig. 2).
Multi-variate analysis of predictors of one-year MACE
Multivariate analysis was conducted by using the mean-
ingful factors in univariate analysis and the other factors
that have been reported to improve the prognosis of patients
with acute MI. These factors included administration of
angiotensin receptor blocker, statin, platelet glycoprotein
IIb/IIIa inhibitor, and low molecular weight heparin.
The predictors for one-year MACE were found to be old
age, a higher Killip class, a lower ejection fraction, a higher
TIMI risk score, and late invasive treatment strategy
(Table 6). 
Early invasive strategy improved the one-year outcome
in logistic regression model to derive a propensity score
analysis (Table 7).
Acute coronary syndrome has been categorized into unst-
able angina, NSTEMI, and STEMI.12 The most effective
treatment for acute coronary syndrome is revascularization
via performing PCI.13 Many clinical studies have been
carried out to decide the optimal time for performing
coronary intervention for NSTEMI patients. Our results
demonstrated that an early invasive strategy is effective for
reducing the long-term outcome in high-risk patients. The
relative risks for long-term outcome in these patients were
Non-ST Elevation Myocardial Infarction in KAMIR
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Table 6. Multi-Variate Analysis for the Predictors of One-Year Major Adverse Cardiac Events
Odd ratio
95% confidence interval
p
Lower Upper
Old age (≥ 65 age) 2.079 1.571 2.751 < 0.001
High Killip class (≥ class II) 1.749 1.546 1.977 < 0.001
Low ejection fraction (≤ 40%) 1.027 1.016 1.037 0.001
Late invasive treatment strategy 1.393 1.100 1.764 0.006
High TIMI risk score (≥ 5 points) 1.290 1.045 1.591 0.018
Treatment of beta blocker 0.762 0.588 0.988 0.041
Treatment of statin 0.772 0.601 0.992 0.043
Diabetes mellitus 1.272 0.969 1.607 0.083
ST segment depression 1.262 0.944 1.686 0.117
High level of high sensitivity C-reactive protein 1.002 0.999 1.005 0.117
Treatment of platelet glycoprotein IIb / IIIa inhibitor 0.658 0.389 1.112 0.118
Treatment of angiotensin receptor blocker 0.771 0.550 1.080 0.130
Treatment of angiotensin converting enzyme inhibitor 0.818 0.621 1.076 0.151
High level of N-terminal pro-brain natriuretic peptide 1.161 0.817 1.649 0.405
Treatment of low molecular weighted heparin 0.918 0.720 1.171 0.492
High level of troponin I 0.999 0.996 1.003 0.687
High level of troponin T 1.000 0.997 1.002 0.803
TIMI, Thrombolysis In Myocardial Infarction
Table 7. Comparison of the Estimated Early Invasive Strategy of One Year Outcome Using Multivariable 
Logistic Regression, Regression Adjustment with the Propensity Score
No Odds ratio
95% confidence 
p value
internal
Crude model 2,845 0.609 0.475 - 0.808 0.004
Multivariable model 2,845 0.718 0.492 - 0.850 0.006
Regression adjusted with propensity score 
2,845 0.505 0.280 - 0.910 0.023
(deciles multivariable)
DISCUSSION
different according to age, gender, diabetes, ST-segment
changes, and renal function. These findings were com-
parable to the previously reported clinical trials.9,14-17
In five large, randomized trials18-22 [Veterans Affairs Non-
Q-Wave Infarction Strategies in Hospital (VANQWISH),
Fragmin and Fast Revascularization during Instability in
Coronary Artery Disease (FRISC) II, Treat Angina with
Aggrastat and Determine the Cost of Therapy with an
Invasive or Conservative Strategy-Thrombolysis in Myo-
cardial Infarction 18 (TACTICS-TIMI 18), TIMI IIIB and
the Third Randomized Intervention Treatment of Angina
(RITA-3)], a routine, early invasive strategy (early angio-
graphy followed by revascularization, depending on the
angiographic findings) was compared with a “conservative”
strategy (angiography and subsequent revascularization
only if medical therapy failed or substantial residual ische-
mia was documented). An early invasive strategy was
shown to be beneficial by the FRISC II, TACTICS-TIMI
18 and RITA-3 studies, especially in the subgroup of
patients who were at a high risk, such as those patients
presenting with an elevated cardiac troponin level. How-
ever, the most recent randomized ICTUS trial showed that
an early invasive strategy was not superior to an early
conservative strategy, even for the high risk patients, on
the short-term and long-term clinical follow-up.5,6
Recent guidelines recommended an early invasive ap-
proach for the high-risk NSTEMI patients. In our study, an
early invasive strategy was better than a late invasive
strategy for patients with NSTEMI, especially for the high
risk patients. We defined the high risk patient who had
higher than 5 points of TIMI risk score and when early
invasive strategy as door to balloon time was within 48
hours. Our present results were not in accordance with those
of the previous trials owing to differences in the study
design, particularly the risk profile of patients included and
the definition of the end points. There are several possible
explanations for the observed differences in outcome
between the present study and the previous trials. First, the
revascularization rate was higher in our study (96.5% for
the early invasive strategy group and 78.8% for the late
invasive strategy group during hospitalization) as compared
with those in the ICTUS (76% vs. 40%, respectively),
TIMI-IIIb (64% vs. 58%, respectively), VANQWISH
(44% vs. 33%, respectively), FRISC II (77% vs. 37%, res-
pectively), TACTICS-TIMI 18 (61% vs. 44%, respectively),
and RITA-3 (57% vs. 28%, respectively). The patients in
our study had higher cardiac troponin I levels (26.6 ng/mL
in group I and 18.1 ng/mL in group II) as compared with
those of other studies. Therefore, the patients who were
enrolled in our study were generally at a higher risk.
Second, myocardial damage that is related to the PCI is a
disadvantage of early invasive treatment. The prognostic
implications of peri-procedural myocardial damage are
controversial.23,24 However, some reports suggested that the
prognosis of patients with such injury should be regarded
to be similar to that of patients with spontaneous necrosis.
Long term follow-up is necessary to determine whether the
increased incidence of procedure-related myocardial da-
mage in the early invasive strategy group in our study
eventually results in a worse prognosis.
This study has some limitations. First, our study is multi-
center prospective registry study, and it is not randomized,
and controlled. Therefore, there was probably a selection
bias when enrolling patients in both groups. The level of
cardiac enzymes was higher in group I patients than that in
group II patients. The patients who complained of ongoing
chest pain were more frequent in group I as compared with
group II. High levels of cardiac enzymes25,26 and ongoing
chest pain are representative markers of progressive myo-
cardial ischemia. There was also a tendency for the
doctors to perform early invasive treatment for patients
with high levels of cardiac enzyme. Thus, the high risk
patients could be included in group I. Second, the patients
who underwent coronary bypass grafting were highly
prevalent in group II. We thought that difficulty lesions
were more common in group II. These findings might
have affected the association of early invasive treatment
with better clinical results. Finally, the duration of our
study was relatively short. Our study is a comparison of
the MACE at one-year. The ICTUS study had 4-years of
follow-up data and the VANQWISH had 23-months of
follow-up data. In conclusion, our findings suggested that
an early invasive strategy could improve long-term
outcome for the KAMIR patients with high risk (ex-
ceeding 5 points of TIMI risk score). 
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